Lifecore Biomedical (NASDAQ:LFCR) Stock, Quote.Headers.trade-ideas

Lifecore Biomedical

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Wall Street

Equities

Market Summary

News

Economics

Federal Reserve

Pre-Market Outlook

Markets

General

BMBL

LFCR

ONDS

SPSC

TLSA

TSLA

U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.

US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus

5 Stocks To Watch Heading Into Tuesday

Earnings

Trading Ideas

US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection &amp; UDR report strong quarters.

Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday

Nio Photo by Sundry Photography on Shutterstock

XPEV

Nio, Li Auto And 3 Stocks To Watch Heading Into Thursday

Lifecore Biomedical Inc

Needham analyst Ryan MacDonald reiterates Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Buy and maintains $25 price target.

Price Target

Reiteration

Analyst Ratings

PRVA

Needham Reiterates Buy on Privia Health Gr, Maintains $25 Price Target

BMO Capital analyst Brian Pitz maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $825 to $1000.

NFLX

BMO Capital Maintains Outperform on Netflix, Raises Price Target to $1000

VIAV

VIAVI Solutions Introduced The Teravm AI Ran Scenario Generator, The Evolution Of The Company's Market-leading Ran Intelligent Controller Test Platform

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) reported quarterly earnings of $1.72 per share which beat the analyst consensus estimate of $1.56 by 10.26 percent. This is a 33.33 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.847 billion which beat the analyst consensus estimate of $4.653 billion by 4.17 percent. This is a 8.65 percent increase over sales of $4.461 billion the same period last year.

Earnings Beats

Bank of New York Mellon Q4 2024 Adj. EPS $1.72 Beats $1.56 Estimate, Sales $4.847B Beat $4.653B Estimate

TD Securities analyst Aaron Macneil initiates coverage on TC Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRP#TSX">TRP</a>) with a Buy rating and announces Price Target of C$73.

Initiation

TSX:TRP

TD Securities Initiates Coverage On TC Energy with Buy Rating, Announces Price Target of C$73

KROS

Keros Therapeutics Announces Additional Update On The Phase 2 TROPOS Trial: Company Says It Voluntarily Halted All Dosing In The TROPOS Trial Based On The Ongoing Safety Review Due To New Observations Of Pericardial Effusion Adverse Events

Needham analyst Joshua Reilly reiterates Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) with a Buy and maintains $40 price target.

VRNT

Needham Reiterates Buy on Verint Systems, Maintains $40 Price Target

Trilogy Metals Announce The Positive Results Of Its Preliminary Economic Assessment Study Or The Bornite Copper Project In The Ambler Mining District Of Northwestern Alaska

Parsons Announced That It Has Initiated A Task Order Extension Supporting The San Diego Pure Water Program

Arthur Hayes, co-founder of cryptocurrency exchange&nbsp;BitMEX&nbsp;and Chief Investment Officer at&nbsp;Maelstrom&nbsp;Fund, stated that Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) will thrive regardless of any government support or regulatory clarity under the incoming Donald Trump administration.
What Happened: In an interview with Benzinga, Hayes questioned the narrative that cryptocurrency-friendly regulations will serve as a bullish catalyst for the market
&#8220;Remember that we got to a total cryptocurrency market cap of over $3 trillion with no government support anywhere in the world. Why do we need it now?&#8221; Hayes argued.
As for Bitcoin, Hayes said that the leading cryptocurrency will flourish in spite of any regulations that would be enacted by Trump.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Hayes expressed doubt on potential cryptocurrency-friendly policies under Trump, saying that most of them will only benefit his lobbyists and close advisors.
&#8220;I fear that the crypto regulation that Trump enacts will be a Frankenstein bill that is an inchoate mishmash of different policies desired by this or that close advisor or large campaign donor,&#8221; he said.
&#8220;It will be a gift to lobbyists and lawyers and will not ultimately bring that much clarity, as it will be impossible to comply with unless you have hundreds of millions of dollars to spend on lawyers.&#8221;
Hayes has been a long-time Bitcoin bull, projecting the apex cryptocurrency to hit $1 million in the long term. 
Why It Matters: Hayes&#8217; remarks come at a time when the incoming Trump administration is expected to significantly alter the landscape of cryptocurrency regulation. 
Recent reports suggested that Trump could issue <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42962279/trump-could-sign-crypto-related-executive-orders-on-day-1-report">executive orders on day one of his presidency</a>, possibly addressing de-banking and&nbsp;<a href="https://www.benzinga.com/24/12/42502213/new-crypto-accounting-standards-from-todaywill-it-boost-bitcoins-corporate-adoption" target="_blank" rel="noreferrer noopener">fair value accounting</a>, which requires banks holding cryptocurrencies to count them as liabilities on their balance sheet.
Trump has rewarded supporters with high-level appointments in the incoming administration. He named venture capitalist David Sacks, who held a <a href="https://www.benzinga.com/24/12/42356067/venture-capitalist-david-sacks-appointed-as-white-house-ai-crypto-czar-by-trump">fundraising event for Trump&#8217;s campaign</a> at his home, as the &#8220;White House A.I. &amp; Crypto Czar.&#8221;
Price Action: At the time of writing, Bitcoin was exchanging hands at $93,573.37, down 0.90% in the last 24 hours, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Regulations

Exclusives

$BTC

MSTR

Trump's Crypto Legislation Will Be A 'Frankenstein' Bill Of Mishmash, Says Arthur Hayes — Bitcoin Doesn't Need Government Support To Flourish

TD Securities analyst Aaron Macneil initiates coverage on Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Buy rating and announces Price Target of C$66.

TSX:ENB

TD Securities Initiates Coverage On Enbridge with Buy Rating, Announces Price Target of C$66

Needham analyst Chris Pierce reiterates Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) with a Buy and maintains $2 price target.

SLDP

Needham Reiterates Buy on Solid Power, Maintains $2 Price Target

Needham analyst Tom Nikic reiterates On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and maintains $64 price target.

ONON

Needham Reiterates Buy on On Holding, Maintains $64 Price Target

TD Securities analyst Aaron Macneil initiates coverage on Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) with a Buy rating and announces Price Target of C$66.

TSX:PPL

TD Securities Initiates Coverage On Pembina Pipeline with Buy Rating, Announces Price Target of C$66

TD Securities analyst Aaron Macneil initiates coverage on South Bow (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SOBO#TSX">SOBO</a>) with a Hold rating and announces Price Target of C$34.

TSX:SOBO

TD Securities Initiates Coverage On South Bow with Hold Rating, Announces Price Target of C$34

On Tuesday, January 14th, U.S. markets closed mixed, with the S&amp;P 500 edging higher and the Nasdaq slipping after a volatile session. Investors evaluated inflation data and prepared for quarterly earnings reports. The producer price index rose less than expected, while elevated Treasury yields and uncertainty surrounding Federal Reserve policy fueled caution. Earnings season kicks off Wednesday, led by major banks.
According to economic data, U.S. producer prices increased by 0.2% in December, down from 0.4% in November, and below market expectations of a 0.3% rise.
Most S&amp;P 500 sectors rose, led by utilities, materials, and financials, while communication services and healthcare declined.
The Dow Jones Industrial Average was up 0.52% and closed at 42,518.28, the S&amp;P 500 closed higher by 0.11% at 5,842.91, while the Nasdaq Composite slid 0.23% to finish at 19,044.39.
Big banks are supposed to kick off the fourth-quarter earnings season today.
Aisa Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed higher by 0.09% at 38,471.50, led by gains in the Transportation Equipment, Chemical, Petroleum &amp; Plastic and Insurance sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 0.22%, ending the session at 8,213.30, led by losses in the IT, Telecoms Services, and Industrials sectors.</li>
<li>India&#8217;s Nifty 50 closed higher by 0.23% at 23,228.55, and the Nifty 500 gained 0.36%, closing at 21,558.75, led by gains in the Power, Real Estate, and Technology sectors.</li>
<li>China&#8217;s Shanghai Composite fell 0.43% and closed at 3,227.12, and the Shenzhen CSI 300 slid 0.64%, finishing the day at 3,796.03.</li>
<li>Hong Kong Hang Seng closed the session higher by 0.34% at 19,286.07.</li>
</ul>
Eurozone at 06:00 AM ET
<ul>
<li>The European STOXX 50 was up 0.36%.</li>
<li>Germany&#8217;s DAX gained 0.67%.</li>
<li>France&#8217;s CAC rose 0.36%.</li>
<li>U.K.&#8217;s FTSE index 100 traded higher by 0.74%.</li>
</ul>
Commodities at 06:00 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.21% at $76.57/bbl, and Brent was up 0.15% at $80.04/bbl.</li>
<li>Natural Gas gained 0.78% to $3.999.</li>
<li>Gold was trading higher by 1.05% at $2,710.76, Silver was up 1.32% to $30.750, and Copper rose 0.10% to $4.3470.</li>
</ul>
U.S. Futures at 06:00 AM ET
Dow futures were up 0.19%, S&amp;P 500 futures rose 0.16% and Nasdaq 100 futures gained 0.21%.
Forex at 06:00 AM ET
<ul>
<li>The U.S. Dollar Index fell 0.11% to 109.06, USD/JPY declined 0.72% to 156.80, and USD/AUD slid 0.14% to 1.6119.</li>
<li>Global stocks rose cautiously ahead of U.S. inflation data and bank earnings, while bond yields dipped. December&#8217;s tame producer price data eased pressure on Treasuries.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Dollar Cools Off Ahead Of Bank Earnings, Asia Markets Mixed, Europe Up - Global Markets Today While US Slept

Needham analyst Chris Pierce reiterates Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) from Buy to Buy.

BLNK

Needham Reiterates Buy on Blink Chargingto Buy

The Company expects to meet its net revenue, adjusted EBITDA, and adjusted diluted EPS guidance, exceed its operating cash flow guidance, and exceed (incur less than) its capital expenditures guidance. The Company also intends to announce that it estimates its net leverage as of December 31, 2024 to be approximately 4x.

Guidance

AMRX

Amneal Pharmaceuticals Expects To Meet Its 2024 Net Revenue, Adjusted EBITDA, And Adjusted EPS Guidance, Exceed Its Operating Cash Flow Guidance - Filing

Needham analyst James Ricchiuti reiterates Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) with a Buy and maintains $145 price target.

AEIS

Needham Reiterates Buy on Advanced Energy Indus, Maintains $145 Price Target

JP Morgan analyst Michael Rehaut maintains KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) with a Neutral and lowers the price target from $82 to $74.5.

JP Morgan Maintains Neutral on KB Home, Lowers Price Target to $74.5

Reports Q2 revenue $32.6M, consensus $29.75M. "The second quarter was a very productive time at Lifecore (LFCR). Our achievements during the period...

Lifecore Biomedical reports Q2 EPS (25c), two estimates (31c)

Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Resources Connection&nbsp;(RGP)&nbsp;up 5...

Closing Bell Movers: Resources Connection gains 5% on earnings

Lifecore Biomedical, Inc. ( ($LFCR) ) has released its Q2 earnings. Here is a breakdown of the information Lifecore Biomedical, Inc. presented to i...

Lifecore Biomedical Reports Q2 Fiscal 2025 Results

Barrington analyst Michael Petusky maintained a Hold rating on Lifecore Biomedical (LFCR – Research Report) today. The company's shares opened toda...

Barrington Keeps Their Hold Rating on Lifecore Biomedical (LFCR)

Lifecore (LFCR) Biomedical announced that it has entered into a sales agreement with a non-competitive buyer for the company's previously purchased...

Lifecore entered into sales agreement for 10-head isolator filler

Lifecore Biomedical to sell multi-purpose 10-head isolator filler

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Lifecore Biomedical (LFCR – Research Report). The company's sh...

Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)

Barrington analyst Michael Petusky has maintained their neutral stance on LFCR stock, giving a Hold rating on January 3. Michael Petusky's rating i...

Lifecore Biomedical's Strategic Asset Sale Supports Hold Rating Amid Leverage Concerns

In a regulatory filing, Lifecore (LFCR) disclosed that its CEO Paul Josephs bought 17K shares of common stock on January 8th in a total transaction...

Comments

Lifecore Biomedical

Lifecore Biomedical (LFCR) Forecast

Lifecore Biomedical (NASDAQ:LFCR) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga